Abu-Baker M Abdel-Aal

Dr. Abu-Baker M Abdel-Aal

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2014 in ChemBioChem
Verified
Journal Article
Closed access
PDF file
AAAbu-Baker M Abdel-Aal
Abu-Baker M Abdel-Aal
VLVani Lakshminarayanan
Vani Lakshminarayanan
PTPamela Thompson
Pamela Thompson
NSNitin Supekar
Nitin Supekar
JBJudy M. Bradley
Judy M. Bradley
GBGeert‐Jan Boons
Geert‐Jan Boons

12 December 2007 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
AAAbu-Baker M Abdel-Aal
Abu-Baker M Abdel-Aal
MBMichael R. Batzloff
Michael R. Batzloff
YFYoshio Fujita
Yoshio Fujita
NBNadia Barozzi
Nadia Barozzi
AFAndres Faria
Andres Faria
Istvan TothIstvan Toth
Istvan Toth

12 January 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MZMehfuz Zaman
Mehfuz Zaman
AAAbu-Baker M Abdel-Aal
Abu-Baker M Abdel-Aal
YFYoshio Fujita
Yoshio Fujita
KPKaren S. M. Phillipps
Karen S. M. Phillipps
MBMichael R. Batzloff
Michael R. Batzloff
Istvan TothIstvan Toth
Istvan Toth
Streptococcus pyogenes (group A streptococcus, GAS) is a Gram-positive bacterial pathogen responsible for a wide variety of diseases. To date, GAS vaccine development has focused primarily on the M-protein. The M-protein is highly variable at the amino (N)-terminus (determining serotype) but is conserved at the carboxyl (C)-terminus. Previously a 29 amino acid peptide (named J14) from the conserved region of the M-protein was identified as a potential vaccine candidate. J14 was capable of eliciting protective antibodies that recognized many GAS serotypes when co-administered with immuno-stimulants. This minimal epitope however showed no immunogenicity when administered alone. In an attempt overcome this immunological non-responsiveness, we developed a self-adjuvanting vaccine candidate composed of three components: the B-cell epitope (J14), a universal helper T-cell epitope (P25) and a lipid moiety consisting of lipoamino acids (Laas) which target Toll-like receptor 2 (TLR2). Immunological evaluation in B10.BR (H-2k) mice demonstrated that the epitope attachment to the point of lipid moiety, and the length of the Laa alkyl chain have a profound effect on vaccine immunogenicity after intranasal administration. It was demonstrated that a vaccine featuring C-terminal lipid moiety containing alkyl chains of 16 carbons, with P25 located at the N-terminus, and J14 attached to the side chain of a central lysine residue was capable of inducing optimal antibody response. These findings have considerable relevance to the development of a broad spectrum J14-based GAS vaccine and in particular provided a rational basis for peptide vaccine design based on this self-adjuvanting lipopeptide technology.

1 March 2010 in Vaccine
Verified
Journal Article
Closed access
MZMehfuz Zaman
Mehfuz Zaman
AAAbu-Baker M Abdel-Aal
Abu-Baker M Abdel-Aal
KPKaren S.M. Phillipps
Karen S.M. Phillipps
YFYoshio Fujita
Yoshio Fujita
MGM.F. Good
M.F. Good
Istvan TothIstvan Toth
Istvan Toth

18 April 2016 in Journal of Peptide Science
Verified
Journal Article
Open access
PDF file
AAAbu-Baker M Abdel-Aal
Abu-Baker M Abdel-Aal
George PapageorgiouGeorge Papageorgiou
George Papageorgiou
RRRichard Raz
Richard Raz
MQMartin Quibell
Martin Quibell
FBFabienne Burlina
Fabienne Burlina
JOJohn Offer
John Offer
A backbone amide bond protecting group, 2‐hydroxy‐4‐methoxy‐5‐nitrobenzyl (Hmnb), improved the synthesis of aggregation and aspartimide‐prone peptides. Introduction of Hmnb is automated and carried out during peptide assembly by addition of 4‐methoxy‐5‐nitrosalicylaldehyde to the peptidyl‐resin and on‐resin reduction to the secondary amine. Acylation of the hindered secondary amine is aided by the formation of an internal nitrophenol ester that undergoes a favourable O,N intramolecular acyl transfer. This activated ester participates in the coupling and generally gives complete reaction with standard coupling conditions. Hmnb is easily available in a single preparative step from commercially available material. Different methods for removing the amide protecting group were explored. The protecting group is labile to acidolysis, following reduction of the nitro group to the aniline. The two main uses of backbone protection of preventing aspartimide formation and of overcoming difficult sequences are demonstrated, first with the synthesis of a challenging aspartimide‐prone test sequence and then with the classic difficult sequence ACP (65‐74) and a 23‐mer homopolymer of polyalanine.

25 September 2012 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MZMehfuz Zaman
Mehfuz Zaman
AAAbu-Baker M Abdel-Aal
Abu-Baker M Abdel-Aal
YFYoshio Fujita
Yoshio Fujita
Zyta ZioraZyta Ziora
Zyta Ziora
MBMichael R. Batzloff
Michael R. Batzloff
Istvan TothIstvan Toth
Istvan Toth